Histology of good risk non-seminomatous germ cell tumour (NSGCT) patients following retroperitoneal lymph node dissection (PC-RPLND) after four cycles of etoposide and cisplatin (Epx4)

被引：0

作者：

Patel, MI ^{[1
]}

Beck, SDW ^{[1
]}

Sheinfeld, J ^{[1
]}

机构：

[1] Univ Sydney, Sydney, NSW 2006, Australia

来源：

BJU INTERNATIONAL | 2005年 / 95卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3 / 3

页数：1

共 50 条

[41] Clinical outcome and postoperative chemotherapy requirement in patients with clinical stage IIA and IIB non-seminomatous germ cell tumor (NSGCT) following primary retroperitoneal lymph node dissection: Impact of preoperative serum tumor markers (STM)
Sheinfeld, J
Stephenson, AJ
Motzer, RJ
Bajorin, DF
Bosl, GJ
JOURNAL OF UROLOGY, 2004, 171 (04): : 247 - 247
[42] SAFETY AND EFFICACY OF OUTPATIENT ROBOTIC RETROPERITONEAL LYMPH NODE DISSECTION FOR STAGE 2 NON-SEMINOMATOUS GERM CELL TUMOR PATIENTS WITH/ WITHOUT NEOADJUVANT CHEMOTHERAPY
Mehrdad, Alemozaffar
Jennifer, Lee
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
[43] RAPIDLY ALTERNATING, DOSE-DENSE CHEMOTHERAPY AND RETROPERITONEAL LYMPH NODE DISSECTION (RPLND): OUTCOMES IN PATIENTS WITH HIGH-RISK NOW SEMINOMATOUS GERM CELL TUMOR
Kim, Philip H.
Syan, Sumeet K.
Dorff, Tanya B.
Quinn, David
Skinner, Donald G.
Schuckman, Anne K.
JOURNAL OF UROLOGY, 2009, 181 (04): : 198 - 198
[44] A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors
Bokemeyer, C
Kohrmann, O
Tischler, J
Weissbach, L
Rath, U
Haupt, A
Schoffski, P
Harstrick, A
Schmoll, HJ
ANNALS OF ONCOLOGY, 1996, 7 (10) : 1015 - 1021
[45] NOVEL PREDICTORS OF BENIGN PATHOLOGY IN STAGE IA OR IB PATIENTS WITH NON-SEMINOMATOUS TESTICULAR GERM CELL MALIGNANCY UNDERGOING PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION
Adibi, Mehrad
Cost, Nicholas
Lubahn, Jessica
Romman, Adam
Margulis, Vitaly
JOURNAL OF UROLOGY, 2012, 187 (04): : E374 - E374
[46] LAPAROSCOPIC POST CHEMOTHERAPY RETROPERITONEAL LYMPH-NODE DISSECTION (L-PC-RPLND) IN RESIDUAL MASS FROM NON-SEMINOMATOUS GERM-CELL TUMOURS OF THE TESTIS (NSGCTT): EARLY EVALUATION AND COMPARISON WITH OPEN COUNTERPART
Nicolai, Nicola
Stagni, Silvia
Biasoni, Davide
Catanzaro, Mario
Torelli, Tullio
Piva, Luigi
Necchi, Andrea
Giannatempo, Patrizia
Raggi, Daniele
Lughezzani, Giovanni
Guttilla, Andrea
Colecchia, Maurizio
Salvioni, Roberto
ANTICANCER RESEARCH, 2013, 33 (05) : 2288 - 2289
[47] Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection for men with CII non-seminomatous germ cell tumors and a radiographically normal retroperitoneum.
Karellas, Michael
Carver, Brett S.
Stasi, Jason
Motzer, Robert J.
Bost, George J.
Sheinfeld, Joel
JOURNAL OF UROLOGY, 2007, 177 (04): : 277 - 277
[48] Management of clinical stage (CS) I and II patients with non- seminomatous germ cell tumors of the testis (NSGCTT) avoiding upfront retroperitoneal lymph node dissection (RPLND)
Flechon, A.
El Karak, F.
Salas, C.
Rivoire, M.
Droz, J.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[49] Indication of post-chemotherapy retroperitoneal lymph-node dissection (RPLND) in the treatment of non-seminomatous germ-cell tumors of the testis (NSGCTT):: The case of minimal initial and residual disease.
Tavernier, E
Fléchon, A
Méeus, P
Rivoire, M
Droz, JP
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 406S - 406S
[50] Ongoing study of laparoscopic retroperitoneal lymph-node dissection (L-RPLND) in low risk clinical stage I non seminomatous germ cell testicular tumours (NSGCTT)
Nicolai, Nicola
Biasoni, Davide
Aguilera, Johnny Piedra
Pizzocaro, Giorgio
Piva, Luigi
Stagni, Silvia
Torelli, Tullio
Milani, Angelo
Salvioni, Roberto
JOURNAL OF UROLOGY, 2008, 179 (04): : 241 - 241

← 1 2 3 4 5 →